<DOC>
	<DOCNO>NCT02105675</DOCNO>
	<brief_summary>The purpose study determine whether DCVAC/PCa add onto Standard Care therapy improve survival time patient Metastatic Castration Resistant Prostate Cancer</brief_summary>
	<brief_title>Phase II Study DCVAC/PCa Added Standard Chemotherapy Men With Metastatic Castration Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Men age â‰¥ 18 year Histologically confirm prostate cancer Presence skeletal metastasis ( CT PET MRI ) Disease progression document increase PSA two new lesion Eastern Cooperative Oncology Group ( ECOG ) Performance status 02 Confirmed brain and/or leptomeningeal metastases Prior chemotherapy prostate cancer Peripheral neuropathy Common Toxicity Criteria ( CTC ) grade 2 great Other uncontrolled intercurrent illness Treatment immunotherapy PCa Clinically significant cardiovascular disease Active autoimmune disease require treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Castrate Resistant</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Biological</keyword>
	<keyword>Vaccine</keyword>
</DOC>